De Muynck Benedicte, Van Herck Anke, Sacreas Annelore, Heigl Tobias, Kaes Janne, Vanstapel Arno, Verleden Stijn E, Neyrinck Arne P, Ceulemans Laurens J, Van Raemdonck Dirk E, Lagrou Katrien, Vanaudenaerde Bart M, Verleden Geert M, Vos Robin
Dept of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Contributed equally.
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.01720-2020. Print 2020 Oct.
Long-term survival after lung transplantation (LTx) is hampered by development of chronic lung allograft dysfunction (CLAD). is an established risk factor for CLAD. Therefore, we investigated the effect of eradication on CLAD-free and graft survival.Patients who underwent first LTx between July, 1991, and February, 2016, and were free from CLAD, were retrospectively classified according to presence in respiratory samples between September, 2011, and September, 2016. -positive patients were subsequently stratified according to success of eradication following targeted antibiotic treatment. CLAD-free and graft survival were compared between -positive and -negative patients; and between patients with or without successful eradication. In addition, pulmonary function was assessed during the first year following isolation in both groups.CLAD-free survival of -negative patients (n=443) was longer compared with -positive patients (n=95) (p=0.045). Graft survival of -negative patients (n=443, 82%) was better compared with -positive patients (n=95, 18%) (p<0.0001). Similarly, -eradicated patients demonstrated longer CLAD-free and graft survival compared with patients with persistent Pulmonary function was higher in successfully -eradicated patients compared with unsuccessfully eradicated patients (p=0.035). eradication after LTx improves CLAD-free and graft survival and maintains pulmonary function. Therefore, early detection and eradication should be pursued.
慢性肺移植功能障碍(CLAD)的发展阻碍了肺移植(LTx)后的长期生存。是CLAD的一个既定风险因素。因此,我们研究了根除对无CLAD生存和移植物存活的影响。对1991年7月至2016年2月期间接受首次LTx且无CLAD的患者,根据2011年9月至2016年9月期间呼吸道样本中的存在情况进行回顾性分类。阳性患者随后根据靶向抗生素治疗后根除的成功情况进行分层。比较阳性和阴性患者之间的无CLAD生存和移植物存活;以及根除成功和未成功的患者之间的情况。此外,在两组分离后的第一年评估肺功能。阴性患者(n = 443)的无CLAD生存时间比阳性患者(n = 95)长(p = 0.045)。阴性患者(n = 443,82%)的移植物存活情况比阳性患者(n = 95,18%)好(p < 0.0001)。同样,与持续存在的患者相比,根除的患者表现出更长的无CLAD生存和移植物存活时间。成功根除的患者的肺功能高于未成功根除的患者(p = 0.035)。LTx后根除可改善无CLAD生存和移植物存活,并维持肺功能。因此,应尽早进行检测和根除。 (注:原文中部分关键因素未明确写出具体名称,翻译时保留了英文表述)